Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints

Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints

Source: 
BioSpace
snippet: 

After hitting the American College of Rheumatology 20% (ACR20) improvement mark in two Phase III trials, Janssen Pharmaceutical is planning to seek regulatory approval for Tremfya in adult patients with active moderate to severe psoriatic arthritis.